Theranautilus, a deep-tech company developing nanorobotic solutions for healthcare, has raised $1.2 million in seed funding. The round led by pi Ventures also saw participation from Golden Sparrow Ventures and angel investors including Abhishek Goyal, Founder and CEO of Tracxn, and Lalit Keshre, CEO of Groww. With the recently raised funding, the company aims to commercialise nanorobotics-based medical devices, initially targeting dental care applications. Additionally, the funds will be utilised to develop Theranautilus’s go-to-market strategy and to advance its efforts in extending innovative technology beyond dental applications.
Incubated at the Indian Institute of Science (IISc), Theranautilus was founded in 2020 by Ambarish Ghosh, Dr Debayan Dasgupta, and Dr Peddi Shanmukh Srinivas.
Theranautilus is developing innovative nanorobotic solutions that address critical dental health challenges. This platform aims to aid issues like dental hypersensitivity, which affects over 2 billion people worldwide and represents a $6 billion market.
Unlike traditional treatments that rely on the continuous use of specialised toothpaste, Theranautilus’s approach offers a long-term solution by manoeuvring precision-manufactured nanorobots to targeted locations within dental tissues to deliver biocompatible materials. These materials can be externally triggered to form bio-mimetic structures that repair damaged tissue, providing lasting relief. The treatment will significantly improve people’s lives by providing long-lasting relief from hypersensitivity through just a 10-minute procedure. This technology has been extensively tested in animals and the company aims to launch the first-of-its-kind human trials for a nanorobotic medical device in 2025.
Additionally, the company, backed by international patents and aims to develop and commercialise precision theranostics-based interventions to manage cancer therapy and other diseases.